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BACKGROUND: Recent studies in prostatic tissue suggest that Propionibacterium acnes (P. acnes), a bacterium associated with acne that
normally lives on the skin, is the most prevalent bacterium in the prostate and in men with benign prostatic hyperplasia. Its prevalence
is higher in samples from patients subsequently diagnosed with prostate cancer. The aim of our study was to test whether circulating
levels of P. acnes antibodies are associated with prostate cancer risk and tumour characteristics using plasma samples from a
population-based case–control study.
METHODS: We measured plasma concentration of P. acnes antibodies for 809 cases and 584 controls using a recently developed ELISA
assay. We compared antibody titres between cases and controls using unconditional logistic regression adjusted for batch and
variables associated with the study design (i.e., age, year of selection and centre). The primary analysis included P. acnes titres in
the model as a dichotomous variable using the median value for controls as the cut-off value.
RESULTS: P. acnes antibody titres for both cases and controls ranged from 1:16 (i.e., low concentration) to 1:65536 (i.e., high
concentration; median value¼1:1024). The odds ratio for prostate cancer associated with titres at or above the median value was
0.73 (95% CI 0.58–0.91, P¼0.005). The association appeared to be particularly strong for advanced prostate cancer (AJCC Stage
grouping III–IV) for which the odds ratio was 0.59 (95% CI 0.43–0.81, P¼0.001) but there was insufficient evidence that the
association differed by tumour stage (p heterogeneity¼0.07).
CONCLUSION: These results need to be confirmed in prospective studies but they are consistent with the hypothesis that P. acnes has a
role in prostate cancer.
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Studies investigating a possible association between acne and
prostate cancer risk have reported inconsistent results. These
include a decreased risk associated with facial acne scarring in our
Risk Factors for Prostate Cancer Study (RFPCS) (Giles et al, 2003),
no significant associations in other two studies (Lightfoot et al,
2004; Galobardes et al, 2005), and an increased risk associated with
long-term use of tetracyclines that was assumed to indicate
treatment of severe acne (Sutcliffe et al, 2007). Most of these
studies (Giles et al, 2003; Lightfoot et al, 2004; Galobardes et al,
2005) were investigating acne as a marker of androgen activity in
puberty, under the hypothesis that higher androgen levels might
predispose to both acne and development of prostate cancer.
Subsequent research has indicated another possible connection
between acne and prostate cancer. Recent reports on Propioni-
bacterium acnes (P. acnes), a bacterium associated with acne that
normally lives on the skin and thrives in blocked follicles, suggest
that this bacterium is prevalent in the prostate, it is associated with
acute and chronic prostatic inflammation, and it might have a role
in prostate carcinogenesis (Cohen et al, 2005; Alexeyev et al, 2006).
Our group (RJC and BAS) cultured P. acnes from one-third of a
series of radical prostatectomy specimens and found that P. acnes-
positive specimens were more likely to contain foci of acute or
chronic inflammation than P. acnes-negative specimens (Cohen
et al, 2005). Consistent with these findings Alexeyev et al (2006)
investigating bacterial DNA in prostatic tissue from patients with
benign prostatic hyperplasia found that P. acnes was the most
prevalent bacterium and that its prevalence was higher in samples
from patients subsequently diagnosed with prostate cancer. These
observations led to hypothesise that P. acnes infection in the
prostate gland is positively associated with prostate cancer risk,
with acne considered as a marker of increased immune sensitivity
to P. acnes infection.
The aim of our study was to test whether plasma concentration
of P. acnes antibodies, measured by an ELISA assay we recently
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cancer risk. We tested this hypothesis using the RFPCS,
a population-based case–control study. Although the majority of
studies discussed above have suggested positive associations
between prostate cancer and either acne in puberty or P. acnes
infection in the prostate gland, our RFPCS cohort previously
showed an inverse association between facial scarring and prostate
cancer risk (Giles et al, 2003), therefore a secondary aim of this
study was to investigate this apparently conflicting result.
MATERIALS AND METHODS
Study design and subjects
The RFPCS study was conducted in 1994–1998 in Melbourne and
Perth, Australia. Details of this study were published previously
(Giles et al, 2001; Severi et al, 2003). Cases were men aged less than
70 years at diagnosis with histologically confirmed adenocarcinoma
of the prostate and notified to the population-based Cancer
Registries in the two States during the period between 1994 and
1997. Tumours were staged according to the TNM system
and categorised into American Joint Committee on Cancer stage
groupings (I–IV) (AJCC, 2002). Cases were classified into two
groups according to tumour differentiation: moderate-grade cases
(i.e., Gleason score 5–7) and high-grade cases (i.e., Gleason score
8–10). Men with well-differentiated tumours or Gleason score less
than 5 were excluded. Controls were randomly selected from the
state electoral rolls and frequency matched to cases by 5-year age
group and city of residence at the time of selection in a ratio of one
control per case. Face to face interviews were conducted usually
at the men’s home using questionnaires to capture various
exposures including demographic factors, medical history, anthro-
pometry, radiation exposures, alcohol consumption, smoking,
growth and development, medical and surgical procedures related
to the reproductive organs, diet captured using a detailed food
frequency questionnaire, lifetime history of sexual activity, and
family history of prostate cancer. The interview also included
questions about acne in adolescence. The interviewer was asked
to report ‘obvious’ acne scarring or ‘uncertain’ acne scarring
(e.g., beard). About mid study, additional funding was obtained to
collect blood samples from subjects mainly to extract DNA for
genetic association studies and measure levels of markers in
circulation. The total number of samples available for this study
was 809 for cases and 584 for controls.
Measure of P. acnes antibodies
Anti-P. acnes antibody titres were determined at Tissugen Pty Ltd.
(Perth, Western Australia, Australia) by researchers blinded to the
case–control status of the plasma samples. The assay was
performed as previously described (Shannon et al, 2008), except
that incubation with primary and secondary antibodies (2h each,
with agitation) and the colour development step (30min) were
carried out at 371C. Briefly, the cell wall-associated/secreted
surface proteins harvested from a cultured prostatic P. acnes
isolate, (type II) were purified, resolubilised to 1.5mgml
–1 in
0.05M carbonate buffer (pH 9.6) and coated overnight onto 96-well
ELISA plates. Each plate included no-antigen and no-plasma
blanks plus the positive control plasma sample (diluted to 1:64).
Plasma samples were analysed in duplicate using two-fold serial
dilutions. Absorbance readings were multiplied by a standardisa-
tion factor (the amount required to adjust the positive control to
its mean value of 0.957) to allow accurate comparison of samples
from different runs. The endpoint antibody titre was then
determined as the highest serum dilution giving an absorbance
reading of 0.100 or greater. The coefficient of intra-assay variation
was 5.7% (as calculated from 18 duplicates of positive control in
the same ELISA run) and the inter-assay variation was 6.3% (as
calculated from 18 different ELISA runs of the positive control).
Plasma samples from 69 men were divided into two aliquots to
check the replicability of the measures. The laboratory was blind to
the duplicates that were included at random among the samples
used for the study. As a measure of replicability we used the intra-
class correlation coefficient, which is the proportion of the total
variance due to variation between persons, where the total variance
included a component due to between persons and between
measures.
Statistical methods
The primary hypothesis of association between P. acnes antibody
titres and prostate cancer risk was tested using unconditional
logistic regression with the case–control status as a dependent
variable (Breslow and Day, 1980). P. acnes titres were dichot-
omised using the median value for controls (i.e., 1:1024) and
included as independent variable in the logistic model. Odds ratio
(OR) estimates and their 95% confidence intervals (CI) were
derived under the likelihood theory. We performed secondary
analyses using the tertiles of the distribution of P. acnes titres in
controls and using the original continuous variable. We log2
transformed the continuous variable before inclusion in the model
so that the odds ratio would represent the relative difference in risk
associated with a doubling of the titres. We fitted models adjusted
for self-reported history of acne during adolescence or facial acne
scarring to investigate whether this would affect the association
between P. acnes titres and prostate cancer risk. We also tested the
interaction between P. acnes titres and prostate cancer risk and
self-reported history of acne in adolescence, facial acne scarring
and reference age (age at diagnosis for cases and age at selection
for controls). Odd ratios by tumour stage (stage I–II and stage
III–IV) and grade (moderate-grade and high-grade) were esti-
mated using polytomous logistic regression models. All regression
analyses were adjusted for batch and for variables associated with
the original study design: reference age (o55, 55–59, 60–69),
study centre (Melbourne and Perth), selection year (1994, 1995,
1996, and 1997). Further adjustment for family history of prostate
cancer (i.e., number of first-degree relatives affected), country of
birth (Australia vs others), and self-reported history of benign
prostatic hyperplasia did not materially change the estimates.
We tested whether adult P. acnes antibody titres were associated
with self-reported acne during adolescence or facial acne scarring
by applying linear regression to the logarithm of the inverse of the
titres for controls using history of acne or facial scarring as
predictors. We tested for trend in the odds ratios by comparing the
likelihoods of two models with and without a pseudo-continuous
variable that was constructed first by log2 transforming the
original variable and then by assigning each man in a specific
tertile, the corresponding median value for that tertile. We tested
hypotheses using the likelihood ratio test. All tests were two-sided
and nominal statistical significance was based on Po0.05.
All statistical analyses were performed using Stata/SE 10 (Stata
Corporation, College Station, Texas, USA).
RESULTS
We measured P. acnes antibody titres for a total of 809 cases and
584 controls whose characteristics are described in Table 1. There
was little variation between the duplicates as indicated by the
high intra-class correlation coefficient (0.94; 95% CI 0.91–0.97).
P. acnes antibody titres measured for RFPCS participants
ranged from 1:16 (i.e., low concentration) to 1:65536 (i.e., high
concentration) and the median value was 1:1024. The mean log2
titres for controls with and without a history of acne were 10.6 and
9.8, respectively. The analysis of P. acnes titres for controls showed
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a history of acne in adolescence were 85% higher than titres for
those not reporting a history of acne (P¼0.003). We found similar
results for facial acne scarring (data not shown).
The distribution of P. acnes antibody titres is presented
separately for cases and controls in Figure 1. The median and
range of the titres were the same for cases and controls but samples
with high titres (e.g., 1:2048 or more) appeared to be more
prevalent for controls than for cases. The mean log2 titres for
controls and cases were 10 and 9.7, respectively. When we fitted a
logistic regression model to the titres split in two groups using the
median as cut-off point (1:1024), the odds ratio associated with
titres equal to or above the median compared with titres below the
median was 0.73 (95% CI 0.58–0.91) (Table 2). The odds ratio
was 0.59 (95% CI 0.43–0.81) for advanced prostate cancer (stage
III–IV) and 0.79 (95% CI 0.62–1.01) for early-stage prostate
cancer (stage I–II), but there was insufficient evidence to conclude
that the association differs by tumour stage (p-hetero-
geneity¼0.07). The odds ratios for moderate-grade prostate
cancer were very similar to the odds ratios for high-grade prostate
cancer (p-heterogeneity¼0.8). The association between P. acnes
antibody titres was confirmed when we fitted the logistic
regression including the titres as continuous variables. The odd
ratio for doubling the antibody titres was 0.94 (95% CI 0.90–0.99).
In the analysis by tertiles of the distribution of P. acnes titres
in controls, the odds ratios associated with the second and
third tertiles compared with the first tertile were 1.00 (95% CI
0.76–1.34) and 0.80 (95% CI 0.60–1.06), respectively (test for
linear trend, P¼0.06).
The odds ratios for P. acnes titres did not materially change after
the inclusion of self-reported history of acne or facial acne scarring
in the models (data not shown), indicating that the association
between P. acnes antibody titres and prostate cancer risk is
independent of self-reported history of acne during adolescence or
facial acne scarring.
For self-reported history of acne during adolescence the odds ratio
for overall prostate cancer was 0.93 (95% CI 0.70–1.22). For facial
acne scarring, the odds ratios for overall prostate cancer was 0.66
(95% CI 0.37–1.17) for the obvious compared with the not obvious.
We found no statistically significant evidence of interactions between
P. acnes antibody titres and self-reported history of acne during
adolescence or P. acnes antibody titres and facial acne scarring after
removing men with uncertain acne scarring.
DISCUSSION
The findings from our case–control study suggest that higher
concentrations of circulating P. acnes antibodies measured in
adulthood are associated with decreased risk of prostate cancer,
especially for advanced prostate cancer. The strengths of this study
include the excellent repeatability of the plasma measures, the
population-based design, and the relatively large sample size. One
limitation is the lack of specificity of the P. acnes antibodies for
subtypes prevalent in the prostate. Although the ELISA was
developed from isolates cultured from the prostate, immunoblots
showed that antigens were conserved among other types of
P. acnes and thus our assay could not differentiate between
immune responses raised against P. acnes infection in the prostate
and P. acnes infection in the skin or in other organs. In our
retrospective study blood samples for cases were collected after
diagnosis and we cannot rule out that the antibody titres in our
prostate cancer cases were lowered by the tumour itself or by
androgen-deprivation therapy. However, this is unlikely because
cancer tends to upregulate the antibody-mediated immune
response (Filella et al, 2000; Johansson et al, 2008) and evidence
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Figure 1 Distribution of P.acnes antibody titres for prostate cancer cases and controls from the Australian Risk Factors for Prostate Cancer Study.
Table 1 Characteristics of participants in the Australian Risk Factors for
Prostate Cancer Study
Factor Cases (%) N¼809
a Controls (%) N¼584
a
Reference age
o55years 113 (14) 111 (19)
55–59years 194 (24) 98 (17)
60–69years 502 (62) 375 (64)
Country of birth
Australia 567 (70) 383 (66)
Overseas 241 (30) 200 (34)
Self-reported history of acne in adolescence
No 641 (79) 456 (78)
Yes 167 (21) 125 (22)
Facial acne scarring
Not obvious 735 (91) 518 (89)
Obvious 27 (3) 28 (5)
Uncertain (beard) 35 (4) 37 (6)
aThe number of missing values for cases and controls were: 1 and 1 for country of
birth; 1 and 3 for self-reported history of acne in adolescence; 12 and 1 for facial
acne scarring.
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ysuggests that androgen deprivation therapy may increase, rather
than decrease, immune function and antibody production
(Aragon-Ching et al, 2007).
Since P. acnes induces a strong cell-mediated T-helper type 1
(Th1) immune response (Mouser et al, 2003; Namazi, 2007) a more
likely explanation of our findings is that higher antibody titres
are an indirect marker of increased cell-mediated immunity caused
by P. acnes infection and that this increased immunity protects
from prostate cancer.
Persistent exposure to Th1 cytokines through chronic infection
can result in systemic Th1 polarisation of the immune system
(Romagnani, 2004), therefore, people with a history of acne or
P. acnes-related infection of the prostate gland could be predis-
posed to develop a strong systemic Th1-type immune response.
Th1 immune responses are detrimental to the establishment and
progression of tumours, which typically secrete factors to suppress
Th1 and promote T-helper type 2 (humoral or antibody-mediated)
immunity (Johansson et al, 2008). In prostate cancer patients this
switch to Th2 polarisation occurs in association with development
of metastatic disease (Filella et al, 2000), possibly explaining why
the inverse association between P. acnes titres and prostate cancer
risk would be stronger for advanced-stage disease.
Several lines of evidence support the possible involvement of
immune responses against P. acnes in protection against prostate
cancer. First, P. acnes is a potent immunomodulator that has been
trialed as a cancer treatment in both animals and humans. The
tumouricidal activity of P. acnes is mediated through recruitment
and activation of innate immune cells including macrophages
and natural killer T cells (Ananias et al, 2007). Second, acne has
been indicated as a protective factor against various other
disorders associated with a Th2 immune response, including
melanomas, lymphomas, leukaemias, atopy, allergy, and asthma
(Namazi, 2007). Finally, the inflammation commonly observed
in the prostate gland is predominantly composed of Th1
lymphocytes and macrophages, which indicates a delayed-type
hypersensitivity (Th1-type) immune response (McClinton et al,
1990; Sfanos et al, 2008).
As our study collected blood samples from adult men, we cannot
distinguish between high titres established by acne during puberty
and those arising later in response to prostate infection. Involvement
of immunity levels maintained sincep u b e r t ym a yb ep o s s i b l es i n c e
previous research by Ingham et al (1987) has shown that antibody
titres against P. acnes are established in early puberty and still exist at
similar levels in individuals 65 years old. In that study the mean log2
titres were slightly higher than the ones we found in our case–control
study, but the absolute values cannot be compared directly due to
differences in assay sensitivity. However, since we observed that
higher anti-P. acnes antibody titres were inversely associated with
prostate cancer risk independently of a history of acne during
adolescence, it is possible that in some men higher titres indicate
infection of the prostate gland.
While this study supports our previous finding of an inverse
association between facial acne scarring and prostate cancer risk in
the RFPCS study (Giles et al, 2003), it is difficult to reconcile
this observed inverse association with our previous finding that
P. acnes culture-positive radical prostatectomy specimens were
more likely to contain foci of acute or chronic inflammation
(Cohen et al, 2005). In that study, however, it was not possible to
investigate the correlation between the inflammatory immune
response in the prostate with antibody levels in circulation because
serum was not available.
In conclusion, the inverse association that we have observed
between concentrations of circulating P. acnes antibodies and risk
of prostate cancer needs to be replicated in large prospective
studies to exclude the possibility that the increased concentrations
in cases are caused by the tumour itself or by treatment. If our
finding is confirmed it might open an avenue for the prevention of
this disease.
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